

CORRECTION

Open Access



Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

Cassandra Rayer¹, Maria Nachury², Arnaud Bourreille³, Xavier Roblin⁴, Laurent Peyrin-Biroulet⁵, Stephanie Viennot⁶, Mathurin Flamant⁷, David Laharie⁸, Bénédicte Caron⁵, Marie Dewitte¹, Laurent Siproudhis⁹, Mathurin Fumery¹⁰ and Guillaume Bouguen^{9,11*}

Correction to: BMC Gastroenterology (2022) 22:498
<https://doi.org/10.1186/s12876-022-02583-5>

After publication of this article [1], the authors reported that the given and family names of most authors were incorrectly structured. The correct list of authors is:

Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, Stephanie Viennot, Mathurin Flamant, David Laharie, Bénédicte Caron, Marie Dewitte, Laurent Siproudhis, Mathurin Fumery and Guillaume Bouguen.

The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s12876-022-02583-5>.

*Correspondence:

Guillaume Bouguen
guillaume.bouguen@chu-rennes.fr

¹ CHU Rennes, University Rennes, 35000 Rennes, France

² CHU Lille, University of Lille, Lille, France

³ CHU Nantes, Nantes, France

⁴ CHU Saint-Etienne, Saint-Étienne, France

⁵ Inserm U954 Department of Hepato-Gastroenterology, Department of Gastroenterology, Nancy University Hospital, Vandœuvre-Lès-Nancy, France

⁶ CHU Caen, Caen, France

⁷ Clinique Jules Vernes, Nantes, France

⁸ CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépatogastroentérologie Et Oncologie Digestive, Université de Bordeaux, 33000 Bordeaux, France

⁹ CHU Rennes, University Rennes, INSERM, CIC1414, Institute NUMECAN (Nutrition Metabolism and Cancer), 35000 Rennes, France

¹⁰ Service d'Hépatogastroentérologie Et Oncologie Digestive, CHU Amiens Et PeriTox, UMR IO-1, Université de Picardie, Amiens, France

¹¹ Service Des Maladies de L'Appareil Digestif, 2 Rue Henri Le Guillou, 35033 Rennes Cedex, France

Published online: 02 February 2023

Reference

1. Rayer C, Nachury M, Bourreille A, Roblin X, Biroulet LP, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study. *BMC Gastroenterol.* 2022;22:498. <https://doi.org/10.1186/s12876-022-02583-5>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.